Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts

Meng,Liping; Uzui,Hiroyasu; Guo,Hangyuan; Tada,Hiroshi

doi:10.3892/mmr.2018.8688

Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts

Authors:
- Liping Meng
- Hiroyasu Uzui
- Hangyuan Guo
- Hiroshi Tada
View Affiliations

Affiliations: Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910‑1193, Japan, Department of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: March 6, 2018 https://doi.org/10.3892/mmr.2018.8688
Pages: 6887-6892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiac fibrosis is a major pathological manifestation of diabetic cardiomyopathy (DCM), which leads to cardiac remodeling, dilated cardiomyopathy and congestive heart failure. Human cardiac fibroblasts (HCF) constitute the predominant cell type in the heart and matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are also involved in cardiac fibrosis. However, it is unclear whether high glucose levels affect the expression of MMPs and TIMPs in HCF. Sodium‑glucose cotransporter (SGLT) inhibitors have been developed as therapeutic agents and the anti‑DCM effect of SGLT inhibitors has been demonstrated by previous studies. However, whether SLGT inhibitors protect the diabetic heart by directly inhibiting the SGLTs in HCF in addition to lowering the blood glucose levels, has not yet been determined. In the present study, increased MMP‑2 expression was noted in HCFs in response to high glucose levels, which may be reversed by phlorizin (inhibits both SGLT1 and SGLT2), but not dapagliflozin (inhibits SGLT2). In addition, SGLT1 was revealed to be present in the HCFs and high glucose level was demonstrated to increase SGLT1 expression, which may be attenuated by phlorizin. Therefore it was concluded that high glucose levels induced MMP‑2 expression in the HCFs, potentially by upregulating SGLT1. SGLT1 inhibition may be a novel strategy for the treatment of DCM.

View Figures

View References

1	Fang ZY, Prins JB and Marwick TH: Diabetic cardiomyopathy: Evidence, mechanisms and therapeutic implications. Endocr Rev. 25:543–567. 2004. View Article : Google Scholar : PubMed/NCBI
2	DeCoux A, Lindsey ML, Villarreal F, Garcia RA and Schulz R: Myocardial matrix metalloproteinase-2: Inside out and upside down. J Mol Cell Cardiol. 77:64–72. 2014. View Article : Google Scholar : PubMed/NCBI
3	Li Q, Sun SZ, Wang Y, Tian YJ and Liu MH: The roles of MMP-2/TIMP-2 in extracellular matrix remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol. 62:485–491. 2007. View Article : Google Scholar : PubMed/NCBI
4	Chen SL, Hu ZY, Zuo GF, Li MH and Li B: I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice. BMC Cardiovasc Disord. 14:1502014. View Article : Google Scholar : PubMed/NCBI
5	Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al: Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 373:2117–2128. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J and Parikh SJ: Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 38:1218–1227. 2015. View Article : Google Scholar : PubMed/NCBI
7	Song P, Onishi A, Koepsell H and Vallon V: Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Exp Opin Ther Targets. 20:1109–1125. 2016. View Article : Google Scholar
8	Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R and Yoshimura M: Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One. 10:e01306052015. View Article : Google Scholar : PubMed/NCBI
9	Banerjee SK, Ramani R, Saba S, Rager J, Tian R, Mathier MA and Ahmad F: A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia. Biochem Biophys Res Commun. 360:381–387. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ramratnam M, Sharma RK, D'Auria S, Lee SJ, Wang D, Huang XY and Ahmad F: Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 3:e0008992014. View Article : Google Scholar : PubMed/NCBI
11	Das S, Mandal M, Chakraborti T, Mandal A and Chakraborti S: Isolation of MMP-2 from MMP-2/TIMP-2 complex: Characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane. Biochim Biophys Acta. 1674:158–174. 2004.PubMed/NCBI
12	Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, et al: Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: Relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler. 11:441–446. 2005. View Article : Google Scholar : PubMed/NCBI
13	Liu X, Song X, Lu J, Chen X, Liang E, Liu X, Zhang M, Zhang Y, Du Z and Zhao Y: Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice. Oncotarget. 7:61703–61715. 2016.PubMed/NCBI
14	Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 30:595–602. 1972. View Article : Google Scholar : PubMed/NCBI
15	Jia G, Whaley-Connell A and Sowers JR: Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 61:21–28. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zou C, Liu X, Xie R, Bao Y, Jin Q, Jia X, Li L and Liu R: Deferiprone attenuates inflammation and myocardial fibrosis in diabetic cardiomyopathy rats. Biochem Biophys Res Commun. 486:930–936. 2017. View Article : Google Scholar : PubMed/NCBI
17	Lo SH, Hsu CT, Niu HS, Niu CS, Cheng JT and Chen ZC: Cryptotanshinone inhibits STAT3 signaling to alleviate cardiac fibrosis in type 1-like diabetic rats. Phytother Res. 31:638–646. 2017. View Article : Google Scholar : PubMed/NCBI
18	Wang XW, Zhang FX, Yang F, Ding ZF, Agarwal N, Guo ZK and Mehta JL: Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. Acta Pharmacol Sin. 37:1349–1358. 2016. View Article : Google Scholar : PubMed/NCBI
19	Li J, Dai Y, Su Z and Wei G: MicroRNA-9 inhibits high glucose-induced proliferation, differentiation and collagen accumulation of cardiac fibroblasts by down-regulation of TGFBR2. Biosci Rep. 36:e004172016. View Article : Google Scholar : PubMed/NCBI
20	Meng L, Liu L, Zhou C, Pan S, Zhai X, Jiang C, Guo Y, Ji Z, Chi J, Peng F and Guo H: Polyphenols and polypeptides in chinese rice wine inhibit homocysteine-induced proliferation and migration of vascular smooth muscle cells. J Cardiovasc Pharmacol. 67:482–490. 2016. View Article : Google Scholar : PubMed/NCBI
21	Shi YF, Chi JF, Tang WL, Xu FK, Liu LB, Ji Z, Lv HT and Guo HY: Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine. J Zhejiang Univ Sci B. 14:696–704. 2013. View Article : Google Scholar : PubMed/NCBI
22	Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M and Chandrasekar B: Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol. 65:9–18. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cauwe B and Opdenakker G: Intracellular substrate cleavage: A novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol. 45:351–423. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hughes BG, Fan X, Cho WJ and Schulz R: MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol. 306:H764–H770. 2014. View Article : Google Scholar : PubMed/NCBI
25	Westermann D, Savvatis K, Lindner D, Zietsch C, Becher PM, Hammer E, Heimesaat MM, Bereswill S, Volker U, Escher F, et al: Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation. 124:2082–2093. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM and Feder JN: Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 1:57–92. 2010. View Article : Google Scholar : PubMed/NCBI
27	Jin X, Yi L, Chen ML, Chen CY, Chang H, Zhang T, Wang L, Zhu JD, Zhang QY and Mi MT: Delphinidin-3-glucoside protects against oxidized low-density lipoprotein-induced mitochondrial dysfunction in vascular endothelial cells via the sodium-dependent glucose transporter SGLT1. PLoS One. 8:e686172013. View Article : Google Scholar : PubMed/NCBI
28	Balteau M, Tajeddine N, de Meester C, Ginion A, Des Rosiers C, Brady NR, Sommereyns C, Horman S, Vanoverschelde JL, Gailly P, et al: NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res. 92:237–246. 2011. View Article : Google Scholar : PubMed/NCBI
29	Van Steenbergen A, Balteau M, Ginion A, Ferte L, Battault S, Ravenstein CM, Balligand JL, Daskalopoulos EP, Gilon P, Despa F, et al: Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep. 7:411662017. View Article : Google Scholar : PubMed/NCBI
30	Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M and Mannucci E: Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol. 243:86–90. 2017. View Article : Google Scholar : PubMed/NCBI
31	Ye Y, Bajaj M, Yang HC, Perez-Polo JR and Birnbaum Y: SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 31:119–132. 2017. View Article : Google Scholar : PubMed/NCBI
32	Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, et al: The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 66:1030–1040. 2017. View Article : Google Scholar : PubMed/NCBI